No Data
InventisBio Co., Limited's (SHSE:688382) Market Cap Dropped CN¥1.1b Last Week; Retail Investors Bore the Brunt
InventisBio Gets Regulatory Approval to Market Gesorexel Tablets
Yifang Bio (688382.SH): Class 1 innovative drug Goserelin acetate tablets approved for listing.
Yifang Biology (688382.SH) announced that the company has entered into an agreement with Zhengda Tianqing Pharmaceutical Group Co., Ltd. (referred to as "...
bocom intl: sino biopharm's 3Q24 performance exceeded expectations, acquiring the controlling rights of the first A-share company.
Bocom Intl released a research report stating that sino biopharm (01177) 3Q24 revenue increased by 14.3% year-on-year to 5.47 billion yuan, with adjusted net income increasing by 58.0% to 0.6 billion yuan, both exceeding the bank's expectations. Management maintains the guidance of double-digit revenue growth for the full year. In addition, the company acquired control of Hoauoboo (688656.SH), entering the immune diagnostic track, with an acquisition price of 33.74 yuan/share. After completion, Hoauoboo will become the first subsidiary of sino biopharm listed on the A-share market. The bank believes that its product portfolio will complement the company in the fields of respiratory, autoimmune, and other diseases.
Yifang Biotech Report for the Third Quarter of 2024
Yifang Biotechnology (688382.SH) plans to purchase proprietary technology corresponding to not more than 3 target antibodies to accelerate the progress of new drug development.
Yifang Biological (688382.SH) announced that the company plans to collaborate with Lyvgen Biopharma Ho...
No Data
No Data